Aflac Incorporated is expected to announce its financial results for the second quarter of 2025 after the market closes on August 5, 2025. Analysts predict the company will report earnings of $1.73 per share and revenue of $4.30 billion for the quarter. This announcement comes as the company faces fluctuations in its stock price, which has seen a decline of 1.3% recently.
On Monday, Aflac shares opened at $98.10. The insurance provider boasts a market capitalization of $53.04 billion, with a price-to-earnings ratio of 15.33. The company’s stock has traded within a fifty-two week range, with a low of $95.97 and a high of $115.50. Currently, the firm’s 50-day simple moving average stands at $102.58, while the 200-day average is $105.05.
In a recent development, insider trading activity has caught the attention of investors. Director Joseph L. Moskowitz sold 1,000 shares of Aflac stock on May 8, 2025, at an average price of $106.79, totaling $106,790. Following this sale, Moskowitz retained 26,096 shares, valued at approximately $2,786,791.84, marking a 3.69% decrease in his holdings.
Another insider, Director Arthur Reginald Collins, sold 2,750 shares on May 15, 2025, for $290,675. After this transaction, Collins holds 6,728 shares worth $711,149.60, which is a 29.01% decrease in his ownership. In total, corporate insiders have sold 40,750 shares of company stock in the last quarter, valued at around $4,304,295. Insider ownership currently stands at 0.80% of the company’s stock.
Analyst Ratings Reflect Mixed Sentiment
Analysts have weighed in on Aflac’s stock, resulting in a range of ratings. Barclays recently set a price target of $98.00 and rated the stock as “underweight.” Similarly, Wall Street Zen downgraded Aflac from a “hold” to a “sell” rating. Conversely, JPMorgan Chase & Co. raised its price target from $96.00 to $100.00, maintaining a “neutral” rating.
Furthermore, Keefe, Bruyette & Woods increased their price target from $104.00 to $106.00 while maintaining a “market perform” rating. Raymond James Financial adjusted their price objective downwards from $115.00 to $110.00, assigning an “outperform” rating. Currently, three analysts recommend selling the stock, eight suggest holding, and three advise buying, resulting in an average rating of “Hold” and a consensus target price of $108.15.
Aflac’s Business Overview
Aflac, through its subsidiaries, offers supplemental health and life insurance products, primarily operating in two segments: Aflac Japan and Aflac U.S. The Aflac Japan segment provides a variety of insurance products, including cancer, medical, nursing care, and life insurance, alongside savings-type insurance plans.
As Aflac prepares for its upcoming earnings announcement, investors and analysts alike will be keenly watching for any indicators of the company’s performance and future prospects. The results could significantly influence market sentiment, given the current dynamics surrounding its stock.
